Abstracts Archive - Page 2395 of 2425 - ACR Meeting Abstracts

Abstract Number: 399 • 2012 ACR/ARHP Annual Meeting
Can Sustained Remission of Rheumatoid Arthritis Be Predicted? an Analysis From the Japanese National Database of Rheumatic Disease (NinJa)
Yoichiro Haji¹, Mitsumasa Kishimoto¹, Ryo Rokutanda¹, Sachiko Ohde², Gautam A. Deshpande³, Yuri Ohara¹, Chisun Min¹, Yasuhiro Suyama¹, Hisanori Shimizu¹, Ken-ichi Yamaguchi¹, Akira Takeda⁴, Yukio Matsui¹, Masato Okada¹ and Shigeto Tohma⁵, ¹Division of Allergy & Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ²Center for Clinical Epidemiology, St.Luke's Life of Science Institute, Tokyo, Japan, ³Center for Clinical Epidemiology, St. Luke's Life Science Instutute, Tokyo, Japan, ⁴Division of Clinical Immunology & Rheumatology, International University of Health and Welfare Hospital, Nasu-shiobara, Japan, ⁵Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan
Background/Purpose: Achievement of clinical remission in rheumatoid arthritis (RA) is now the goal of therapy to reduce joint damage and disability, and maintain or improve…
Abstract Number: 400 • 2012 ACR/ARHP Annual Meeting
High Patient Global Assessment Scores Associate with the Residual Disease Activity Unidentified by a 28-Joint Examination in Rheumatoid Arthritis Patients Approaching Clinical Remission
Yasushi Inoue¹, Eiichi Tanaka², Ayako Nakajima³, Eisuke Inoue⁴, Akiko Kobayashi⁴, Daisuke Hoshi¹, Naoki Sugimoto⁴, Kumi Shidara⁴, Yohei Seto⁴, Atsuo Taniguchi⁴, Shigeki Momohara¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Tokyo Women's Medical University, Tokyo, Japan, ³Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Patient global assessment (PtGA) is a component of the new ACR/EULAR remission criteria for rheumatoid arthritis (RA). It has been reported that >50% of…
Abstract Number: 401 • 2012 ACR/ARHP Annual Meeting
Can We Improve Outcomes in Early Rheumatoid Arthritis by Determining Best Practices? An Analysis of the Canadian Early Rheumatoid Arthritis Cohort (CATCH)
Jamie Harris¹, Vivian P. Bykerk², Carol A. Hitchon³, Edward Keystone⁴, J. Carter Thorne⁵, Gilles Boire⁶, Boulos Haraoui⁷, Glen S. Hazlewood⁸, Ashley Bonner⁹, Janet E. Pope¹⁰ and CATCH Investigators¹¹, ¹Western University, London, ON, Canada, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³University of Manitoba, Winnipeg, MB, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁷Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ⁸Medicine, University of Toronto, Toronto, ON, Canada, ⁹McMaster University, Hamilton, ON, Canada, ¹⁰Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ¹¹Toronto, ON, Canada
Background/Purpose: The goal of ERA treatment is remission but many patients do not achieve this state due to patient factors and perhaps differences in treating…
Abstract Number: 402 • 2012 ACR/ARHP Annual Meeting
Discordant Inflammatory Markers in Veterans with Rheumatoid Arthritis: Baseline Characteristics and Relationship with Disease Activity
Rebecca Belsom¹, Archana Jain¹, Jeffrey R. Curtis², Shuo Yang³, Ted R. Mikuls⁴, Lang Chen⁵ and Angelo L. Gaffo⁶, ¹Rheumatology, University of Alabama, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁵Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Medicine, Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Discrepancies between erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) elevations with clinical disease activity frequently occur in rheumatoid arthritis (RA) patients and may…
Abstract Number: 403 • 2012 ACR/ARHP Annual Meeting
The Impact of Reaching Low Disease Activity in the First Year On Future Disability and Damage in Patients with Early Rheumatoid Arthritis
Pooneh Akhavan¹, George A. Tomlinson², Paul R. Fortin³ and Claire Bombardier¹, ¹Rheumatology, University of Toronto, Toronto, ON, Canada, ²Dept of Medicine/Rheumatology, Toronto General Hospital, Toronto, ON, Canada, ³Medicine, Centre de Recherche du Chu de Québec et Université Laval, Quebec City, QC, Canada
Background/Purpose: Remission has been proposed as the goal of treatment in patients with early rheumatoid arthritis (RA) by current clinical practice guidelines. Remission is ideal…
Abstract Number: 404 • 2012 ACR/ARHP Annual Meeting
Remission is a Difficult Target in Clinical Practice When RA Disease Is Established
Till Uhlig¹, Elisabeth Lie², Cecillie Kaufmann³, Erik Rødevand⁴, Knut Mikkelsen⁵, Synnøve Kalstad⁶ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology department, Vestre Viken, Drammen, Norway, ⁴Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway, ⁵Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁶Dept. of Rheumatology, University Hospital of Northern Norway, Tromsø, Norway
Background/Purpose: Clinical remission is the treatment target in rheumatoid arthritis (RA) and several composite indices are available for evaluation of remission and low disease activity…
Abstract Number: 405 • 2012 ACR/ARHP Annual Meeting
Frequencies of Boolean and Index Based ACR-EULAR Remissions Differ Slightly Depending On the Method of Patient Global Assessment
Paul Studenic¹, Josef S. Smolen¹ and Daniel Aletaha², ¹Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Two definitions of remission have been put forward by the ACR and EULAR: a Boolean based, requiring swollen and tender joint counts (SJC, TJC),…
Abstract Number: 406 • 2012 ACR/ARHP Annual Meeting
βig-h3 Regulates the Inflammatory Arthritis by Mediating Selective Recruitment of Effector/Memory T Cells
Keum Hee Sa¹, Jin Hee Kang¹, Mahmudul Md Alam¹, Kyung Hwa Lee¹, Churl Hyun Im¹, Eon Jeong Nam¹, In San Kim² and Young Mo Kang³, ¹Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea, ²Biochemistry & Cell Biology, Cell and Matrix Research Institute, Kyungpook National University School of Medicine, Daegu, South Korea, ³Department of Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea
Background/Purpose: Transforming growth factor-beta inducible gene-h3 (βig-h3) is abundantly expressed in synovial tissues of rheumatoid arthritis (RA) and has a regulatory role in growth, differentiation,…
Abstract Number: 407 • 2012 ACR/ARHP Annual Meeting
The I50V IL4R SNP Is Associated with Increased Th17 Cell Frequency and Poor Clinical Outcome in Rheumatoid Arthritis
Jan Leipe¹, Iryna Prots², Markus A. Schramm¹, Matthias Witt¹, Axel P. Nigg¹, Christiane S. Reindl¹, Claudia Dechant¹, Mathias Grunke¹, Hendrik Schulze-Koops¹ and Alla Skapenko³, ¹Division of Rheumatology and Clinical Immunology, Med. Klinik und Poliklinik IV, University of Munich, Munich, Germany, ²Friedrich-Alexander-University Erlangen-Nürnberg, Junior Research Group III, Interdisciplinary Center for Clinical Research Nikolaus-Fiebiger Center for Molecular Medicine, Erlangen, ³Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany
Background/Purpose: A single nucleotide polymorphism (SNP) in the IL4R gene (I50V, rs 1805010) has previously been associated with an aggressive destructive course of rheumatoid arthritis…
Abstract Number: 408 • 2012 ACR/ARHP Annual Meeting
Alpha-Enolase Facilitates Migration of Fibroblast-Like Synoviocytes in Rheumatoid Arthritis
Kichul Shin¹, Ji Ah Park², Seyeon Bae³, Jae Seung Kang³ and Yeong Wook Song⁴, ¹Rheumatology, College of Medicine, Seoul National University, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine,, Seoul National Hospital, Seoul, South Korea, ³Department of Anatomy and Tumor Immunity Medical Research Center, College of Medicine, Seoul National University, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea
Background/Purpose:Alpha-enolase (ENO1) is a multifunctional glycolytic enzyme ubiquitously expressed in the cytoplasm. Citrullinated ENO1 is reported to be a candidate autoantigen in rheumatoid arthritis (RA),…
Abstract Number: 409 • 2012 ACR/ARHP Annual Meeting
Pathway Analysis of Genome-Wide Association Studies On Rheumatoid Arthritis
Young Ho Lee¹, Sung Jae Choi², Jong Dae Ji² and Gwan Gyu Song³, ¹Internal Medicine, Rheumatology, Korea University Medical Center, Seoul, South Korea, ²Rheumatology, Korea University Medical Center, Seoul, South Korea, ³Div of Rheum, Dept of Int Med, Korea Univ College of Med, Seoul, South Korea
Background/Purpose: Genome-wide association studies (GWASs) have been successfully used to identify novel common genetic variants that contribute to susceptibility to complex diseases, but individual GWASs…
Abstract Number: 370 • 2012 ACR/ARHP Annual Meeting
Characteristic of the Japanese Patients with Rheumatoid Arthritis (RA) of Rapid Radiographic Progression (RRP) Treated with Synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Daily Practice: A Large-Scale Prospective Longitudinal Cohort Study (the 1st report of Apple Survey)
Akitomo Okada¹, Atsushi Kawakami², Takaaki Fukuda³, Toshihiko Hidaka⁴, Tomonori Ishii⁵, Yukitaka Ueki⁶, Takao Kodera⁷, Munetoshi Nakashima⁸, Yuichi Takahashi⁹, Seiyo Honda¹⁰, Yoshiro Horai², Tomohiro Koga¹, Ryu Watanabe¹¹, Hiroshi Okuno¹² and Katsumi Eguchi¹³, ¹Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Center for Rheumatic Diseases, Kurume University Medical Center, Kurume, Japan, ⁴Zenjinkai Shimin-No-Mori Hospital, Miyazaki, Japan, ⁵Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, ⁶Sasebo Chuo Hospital, Sasebo, Japan, ⁷Tohoku Kosei Nenkin Hospital, Sendai, Japan, ⁸Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ⁹Yu Family Clinic, Sendai, Japan, ¹⁰Kurume University School of Medicene, Kurume, Japan, ¹¹Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan, ¹²Tohoku University Hospital, Sendai, Japan, ¹³Sasebo City General Hospital, Sasebo, Nagasaki, Japan
Background/Purpose: There has been few epidemiological report of longitudinal radiographic progression in rheumatoid arthritis (RA) patients captured in daily practice. In 20 related-centers of the…
Abstract Number: 371 • 2012 ACR/ARHP Annual Meeting
Treat-to-Target Strategy Aiming At Achievement of Structural and Functional Remission in Patients with Active Elderly-Onset Rheumatoid Arthritis
Takahiko Sugihara¹, Tatsuro Ishizaki², Tadashi Hosoya¹, Shoko Iga¹, Waka Yokoyama¹, Fumio Hirano¹, Nobuyuki Miyasaka³ and Masayoshi Harigai⁴, ¹Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ²Human Care Research Team, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan, ³Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: Treat-to-target is the consensus treatment strategy for patients with rheumatoid arthritis (RA), but supporting evidence for treat-to-target strategy in elderly RA patients in clinical…
Abstract Number: 372 • 2012 ACR/ARHP Annual Meeting
TRAF1/C5 Locus Is Associated with Response to Anti-Tumor Necrosis Factor Therapy in Patients with Rheumatoid Arthritis
Helena Canhao¹, Ana M. Rodrigues², Maria José Santos³, Diana Carmona-Fernandes⁴, Bruno Bettencourt⁵, Jing Cui⁶, Fabiana Rocha⁵, Jose canas Silva³, Joaquim Polido Pereira⁷, Jose Alberto Pereira Silva⁸, José Antonio Costa⁹, Domingos Araujo¹⁰, Candida Silva¹¹, Helena Santos¹², Catia Duarte¹³, Fernando Pimentel-Santos¹⁴, Jaime C. Branco¹⁴, Robert M. Plenge¹⁵, Daniel H. Solomon¹⁶, Jacome Bruges Armas⁵, José A. P. Da Silva¹⁷, João E. Fonseca¹⁸ and Elizabeth W. Karlson¹⁹, ¹Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Instituto de Medicina Molecular, Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Lisbon, Portugal, ²2- Rheumatology Research Unit,, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Lisbon, Portugal, ³Rheumatology Department, Hospital Garcia de Orta, E.P.E., Almada, Portugal, ⁴Rheumatology Research Unit Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, ⁵Seebmo, Hospital de Santo Espirito da Ilha Terceira, Ilha Terceira, Portugal, ⁶Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁷Rheumatology Research Unit, Instituto Medicina Molecular, Lisbon, Portugal, ⁸Rheumatology Department, Santa Maria Hospital, Lisbon, Portugal, ⁹Rheumatology, Centro Hospitalar do Alto Minho, Hospital de Ponte de Lima, Ponte de Lima, Portugal, ¹⁰Rheumatology Department, Unidade Local de Saude, Ponte de Lima, Portugal, ¹¹Reumatology, Instituto Portugues Reumatologia, Lisbon, Portugal, ¹²Rheumatology, Instituto Português de Reumatologia, Lisboa, Portugal, ¹³Rheumatology, Hospitais da Universidade de Coimbra, Coimbra, Portugal, ¹⁴Rheumatology, Centro Hospitalar de Lisboa Ocidental, Hospital Egas Moniz, Lisboa, Portugal, ¹⁵Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ¹⁶Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ¹⁷Serviço de Reumatologia, Centro Hospitalar e Universitário de Coimbra – Hospitais da Universidade de Coimbra, E.P.E., Coimbra, Portugal, ¹⁸Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa and Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisboa, Portugal, ¹⁹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Some of the allelic variants associated with rheumatoid arthritis (RA) susceptibility are related to tumor necrosis factor (TNF) signaling pathways. We hypothesized that they…
Abstract Number: 373 • 2012 ACR/ARHP Annual Meeting
Patient-Reported Outcomes in Early Rheumatoid Arthritis Patients Failing to Achieve Stable Low Disease Activity: Comparing Addition of Adalimumab to Methotrexate Monotherapy with Maintenance On Adalimumab Plus Methotrexate
Arthur Kavanaugh¹, Ronald F. van Vollenhoven², Paul Emery³, James W. Shaw⁴, Mary A. Cifaldi⁵, Stefan Florentinus⁶ and Josef S. Smolen⁷, ¹UCSD School of Medicine, La Jolla, CA, ²Karolinska Institute, Stockholm, Sweden, ³Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ⁴Global Health Economics and Outcomes Research, Abbott Laboratories, Abbott Park, IL, ⁵Abbott Laboratories, Abbott Park, IL, ⁶AbbVie, Rungis, France, ⁷Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Treat-to-target guidelines for rheumatoid arthritis (RA) suggest adjusting therapy every 3-6 months for pts who fail to achieve a disease activity target. However, pts…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].